Rai, Vikrant et al. “Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.” Molecular and cellular biochemistry vol. 437,1–2 (2018): 13–36. https://doi.org/10.1007/s11010-017-3092-z

Siegel, Rebecca L et al. “Cancer statistics, 2023.” CA: a cancer journal for clinicians vol. 73,1 (2023): 17–48. https://doi.org/10.3322/caac.21763

American Cancer Society. Cancer Facts & Figures 2025. American Cancer Society, 2025. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancerfacts-figures.html.

Liu D, Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. Biosci Trends. 2021;15(3):142–7. https://doi.org/10.5582/bst.2021.01083.

Article  PubMed  Google Scholar 

Raoul, Jean-Luc et al. “Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.” Cancer treatment reviews vol. 72 (2019): 28–36. https://doi.org/10.1016/j.ctrv.2018.11.002

Forner, Alejandro et al. “Hepatocellular carcinoma.” Lancet (London, England) vol. 379,9822 (2012): 1245–55. https://doi.org/10.1016/S0140-6736(11)61347-0

Liu, Jun et al. “Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma.” Frontiers in immunology vol. 14 1285370. 19 Dec. 2023, https://doi.org/10.3389/fimmu.2023.1285370

Huang, Ao et al. “Targeted therapy for hepatocellular carcinoma.” Signal transduction and targeted therapy vol. 5,1 146. 11 Aug. 2020, https://doi.org/10.1038/s41392-020-00264-x

Kudo, Masatoshi et al. “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.” Lancet (London, England) vol. 391,10126 (2018): 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1

Bruix, Jordi et al. “Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) vol. 389,10064 (2017): 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9

Dhanasekaran, Renumathy et al. “Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.” Gastroenterology vol. 156,2 (2019): 492–509. https://doi.org/10.1053/j.gastro.2018.11.001

Zhu, Andrew X et al. “Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology vol. 20,2 (2019): 282–296. https://doi.org/10.1016/S1470-2045(18)30937-9

Chen, Shuzhen et al. “Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.” Cancer letters vol. 460 (2019): 1–9. https://doi.org/10.1016/j.canlet.2019.114428

Chakraborty, Eesha, and Devanand Sarkar. “Emerging Therapies for Hepatocellular Carcinoma (HCC).” Cancers vol. 14,11 2798. 4 Jun. 2022, https://doi.org/10.3390/cancers14112798

Marei, Hany E et al. “Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.” Cancer cell international vol. 23,1 64. 10 Apr. 2023, https://doi.org/10.1186/s12935-023-02902-0

Ribas, Antoni, and Jedd D Wolchok. “Cancer immunotherapy using checkpoint blockade.” Science (New York, N.Y.) vol. 359,6382 (2018): 1350–1355. https://doi.org/10.1126/science.aar4060

Finn, Richard S et al. “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.” The New England journal of medicine vol. 382,20 (2020): 1894–1905. https://doi.org/10.1056/NEJMoa1915745

Ren, Zhenggang et al. “Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study.” The Lancet. Oncology vol. 22,7 (2021): 977–990. https://doi.org/10.1016/S1470-2045(21)00252-7

An, Yao et al. “Molecular insights into cancer drug resistance from a proteomics perspective.” Expert review of proteomics vol. 16,5 (2019): 413–429. https://doi.org/10.1080/14789450.2019.1601561

Xu, Feng et al. “Immune checkpoint therapy in liver cancer.” Journal of experimental & clinical cancer research : CR vol. 37,1 110. 29 May. 2018, https://doi.org/10.1186/s13046-018-0777-4

Lee, Alvin J X, and Charles Swanton. “Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.” Biochemical pharmacology vol. 83,8 (2012): 1013–20. https://doi.org/10.1016/j.bcp.2011.12.008

Gerlinger, M, and C Swanton. “How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.” British journal of cancer vol. 103,8 (2010): 1139–43. https://doi.org/10.1038/sj.bjc.6605912

Dean, Michael et al. “Tumour stem cells and drug resistance.” Nature reviews. Cancer vol. 5,4 (2005): 275–84. https://doi.org/10.1038/nrc1590

Tian, Yichen et al. “Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.” Current cancer drug targets vol. 22,6 (2022): 454–462. https://doi.org/10.2174/1568009622666220330151725

Llovet, Josep M et al. “Molecular therapies and precision medicine for hepatocellular carcinoma.” Nature reviews. Clinical oncology vol. 15,10 (2018): 599–616. https://doi.org/10.1038/s41571-018-0073-4

Zhao, Hongxing et al. “Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma.” Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 74 (2024): 101084. https://doi.org/10.1016/j.drup.2024.101084

Al-Salama, Zaina T et al. “Lenvatinib: A Review in Hepatocellular Carcinoma.” Drugs vol. 79,6 (2019): 665–674. https://doi.org/10.1007/s40265-019-01116-x

Guo, Jinhui et al. “Resistance of Lenvatinib in Hepatocellular Carcinoma.” Current cancer drug targets vol. 22,11 (2022): 865–878. https://doi.org/10.2174/1568009622666220428111327

Qin, Yongqing et al. “Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy.” Liver international : official journal of the International Association for the Study of the Liver vol. 44,8 (2024): 1808–1831. https://doi.org/10.1111/liv.15953

Xian, Linfeng et al. “Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.” Cellular oncology (Dordrecht, Netherlands) vol. 45,5 (2022): 1019–1036. https://doi.org/10.1007/s13402-022-00707-3

Yin, Yalei et al. “EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.” Journal of experimental & clinical cancer research : CR vol. 38,1 83. 15 Feb. 2019, https://doi.org/10.1186/s13046-019-1082-6

Ao, Junjie et al. “Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.” Biochemical and biophysical research communications vol. 549 (2021): 171–178. https://doi.org/10.1016/j.bbrc.2021.02.097

Ogasawara, Sachiko et al. “Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo.” Anticancer research vol. 39,11 (2019): 5973–5982. https://doi.org/10.21873/anticanres.13802

Zhao, Zhongwei et al. “Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.” Journal of cellular and molecular medicine vol. 25,1 (2021): 549–560. https://doi.org/10.1111/jcmm.16108

Fu, Rongdang et al. “Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.” Medical oncology (Northwood, London, England) vol. 37,4 24. 12 Mar. 2020, https://doi.org/10.1007/s12032-020-01350-4

Ma, Xiao-Lu et al. “CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma.” Journal of hematology & oncology vol. 13,1 11. 5 Feb. 2020, https://doi.org/10.1186/s13045-020-0845-z

Kim, Ki-Hyun, and Hyori Kim. “Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.” Experimental & molecular medicine vol. 49,3 e307. 24 Mar. 2017, https://doi.org/10.1038/emm.2017.17

Carbajo-Pescador S, et al. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109(1):83–91. https://doi.org/10.1038/bjc.2013.285.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, Feng et al. “Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.” Oncology letters vol. 10,2 (2015): 778–784. https://doi.org/10.3892/ol.2015.3315

Liu, Xiaokun et al. “EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.” Apoptosis : an international journal on programmed cell death vol. 29,7–8 (2024): 1161–1184. https://doi.org/10.1007/s10495-024-01967-0

Baghbani, Elham et al. “Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.” Life sciences vol. 282 (2021): 119826. https://doi.org/10.1016/j.lfs.2021.119826

Wang, Tao et al. “Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells.” Cell death and differentiation vol. 25,12 (2018): 2086–2100. https://doi.org/10.1038/s41418-018-0095-6

Abeni, Edoardo et al. “Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.” International journal of oncology vol. 51,1 (2017): 128–144. https://doi.org/10.3892/ijo.2017.4019

Gailhouste, Luc et al. “Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells.” Molecular therapy : the journal of the American Society of Gene Therapy vol. 26,7 (2018): 1840–1854. https://doi.org/10.1016/j.ymthe.2018.04.018

Di Giacomo, Silvia et al. “Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps.” Archives of toxicology vol. 93,3 (2019): 623–634. https://doi.org/10.1007/s00204-019-02395-9

Wang, Haibo et al. “CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.” Molecular medicine reports vol. 12,3 (2015): 3902–3908. https://doi.org/10.3892/mmr.2015.3871

Zhai, Bo et al. “Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.” Molecular cancer therapeutics vol. 13,6 (2014): 1589–98. https://doi.org/10.1158/1535-7163.MCT-13-1043

Luo, Tao et al. “PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression.” Autophagy vol. 12,8 (2016): 1355–71. https://doi.org/10.1080/15548627.2015.1034405

Sun, Xiaofang et al. “Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.” Hepatology (Baltimore, Md.) vol. 64,2 (2016): 488–500. https://doi.org/10.1002/hep.28574

Liang, Yingjian et al. “Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.” Hepatology (Baltimore, Md.) vol. 57,5 (2013): 1847–57. https://doi.org/10.1002/hep.26224

Zhao, Dali et al. “Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.” Cellular signalling vol. 26,5 (2014): 1030–9. https://doi.org/10.1016/j.cellsig.2014.01.026

Dong, Ningning et al. “M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma.” British journal of cancer vol. 121,1 (2019): 22–33. https://doi.org/10.1038/s41416-019-0482-x

Fan, Zhongyi et al. “PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling.” Cancer letters vol. 450 (2019): 132–143. https://doi.org/10.1016/j.canlet.2019.02.040

Karabicici, Mustafa et al. “Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7.” Frontiers in cell and developmental biology vol. 9 639779. 11 Aug. 2021, https://doi.org/10.3389/fcell.2021.639779

Zhou, He-Ming et al. “Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.” Experimental cell research vol. 436,1 (2024): 113956. https://doi.org/10.1016/j.yexcr.2024.113956

Hu, Lili et al. “EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma.” Frontiers in medicine vol. 11 1464610. 13 Nov. 2024, https://doi.org/10.3389/fmed.2024.1464610

Llovet, Josep M et al. “Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.” Nature cancer vol. 3,4 (2022): 386–401. https://doi.org/10.1038/s43018-022-00357-2

Ezzoukhry, Zakaria et al. “EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.” International journal of cancer vol. 131,12 (2012): 2961–9. https://doi.org/10.1002/ijc.27604

Raja, Aroosha et al. “FGF19-FGFR4 Signaling in Hepatocellular Carcinoma.” Cells vol. 8,6 536. 4 Jun. 2019, https://doi.org/10.3390/cells8060536

Kim, Richard D et al. “First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.” Cancer discovery vol. 9,12 (2019): 1696–1707. https://doi.org/10.1158/2159-8290.CD-19-0555

Shen, Bin et al. “EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.” Molecular cancer therapeutics vol. 22,12 (2023): 1479–1492. https://doi.org/10.1158/1535-7163.MCT-23-0096

Abitbol, Shirley et al. “AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.” Journal of hepatology vol. 68,6 (2018): 1203–1213. https://doi.org/10.1016/j.jhep.2017.12.018

Li, Qian et al. “Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.” Cancer science vol. 112,5 (2021): 1695–1706. https://doi.org/10.1111/cas.14861

Wang, Haiyu et al. “The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.” Frontiers in cell and developmental biology vol. 8 55. 7 Feb. 2020, https://doi.org/10.3389/fcell.2020.00055

Bouattour, Mohamed et al. “Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.” Hepatology (Baltimore, Md.) vol. 67,3 (2018): 1132–1149. https://doi.org/10.1002/hep.29496

Lei, Ya-Ruo et al. “Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects.” Frontiers in bioscience (Landmark edition) vol. 29,2 (2024): 52. https://doi.org/10.31083/j.fbl2902052

Galun, Danijel et al. “Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.” Journal of hepatocellular carcinoma vol. 4 93–103. 11 Jul. 2017, https://doi.org/10.2147/JHC.S106529

Duan, Hongxia et al. “Recent advances in drug delivery systems for targeting cancer stem cells.” Acta pharmaceutica Sinica. B vol. 11,1 (2021): 55–70. https://doi.org/10.1016/j.apsb.2020.09.016

Duan, Xuhua et al. “Nrf2-siRNA Enhanced the Anti-Tumor Effects of As2O3 in 5-Fluorouracil-Resistant Hepatocellular Carcinoma by Inhibiting HIF-1α/HSP70 Signaling.” Journal of hepatocellular carcinoma vol. 9 1341–1352. 21 Dec. 2022, https://doi.org/10.2147/JHC.S388077

Shao, Hui et al. “Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.” Applied biochemistry and biotechnology vol. 195,8 (2023): 5217–5237. https://doi.org/10.1007/s12010-023-04511-z

Pu, Yiyi et al. “CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.” Disease markers vol. 2022 6907057. 11 Mar. 2022, https://doi.org/10.1155/2022/6907057

Zhou, Bo et al. “USP39/SMC4 promotes hepatoma cell proliferation and 5-FU resistance.” Scientific reports vol. 15,1 8869. 14 Mar. 2025, https://doi.org/10.1038/s41598-025-93029-x

Fang, Jiayan et al. “TAF15 inhibits p53 nucleus translocation and promotes HCC cell 5-FU resistance via post-transcriptional regulation of UBE2N.” Journal of physiology and biochemistry vol. 80,4 (2024): 919–933. https://doi.org/10.1007/s13105-024-01053-8

Tian, Tao et al. “MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.” Journal of biochemical and molecular toxicology vol. 32,8 (2018): e22167. https://doi.org/10.1002/jbt.22167

Zhang, Yuanbiao et al. “FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.” International journal of oncology vol. 52,5 (2018): 1455–1464. https://doi.org/10.3892/ijo.2018.4327

Zhang, Jing et al. “AUF1 promotes hepatocellular carcinoma progression and chemo-resistance by post-transcriptionally upregulating alpha-fetoprotein expression.” Pathology, research and practice vol. 245 (2023): 154441. https://doi.org/10.1016/j.prp.2023.154441

Hamaya, Sae et al. “Cisplatin in Liver Cancer Therapy.” International journal of molecular sciences vol. 24,13 10858. 29 Jun. 2023, https://doi.org/10.3390/ijms241310858

Xu, Ning et al. “Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.” Biochemical and biophysical research communications vol. 425,2 (2012): 468–72. https://doi.org/10.1016/j.bbrc.2012.07.127

Shi, Liang et al. “miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.” Asian Pacific journal of cancer prevention : APJCP vol. 15,23 (2014): 10439–44. https://doi.org/10.7314/apjcp.2014.15.23.10439

Xie, Binhui et al. “STEAP4 inhibits cisplatin-induced chemotherapy resistance through suppressing PI3K/AKT in hepatocellular carcinoma.” Cancer & metabolism vol. 11,1 26. 18 Dec. 2023, https://doi.org/10.1186/s40170-023-00323-1

Mi L, Kuang H. Melatonin Regulates Cisplatin Resistance and Glucose Metabolism Through Hippo Signaling in Hepatocellular Carcinoma Cells. Cancer management and research. Mar.2020;12(1863–1874):12. https://doi.org/10.2147/CMAR.S230466.

Article  Google Scholar 

Wang F, Zhiming Wu. Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Exp Ther Med. 2018;15(6):5371–6. https://doi.org/10.3892/etm.2018.6086.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiu, Peng et al. “Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.” Cancer science vol. 104,3 (2013): 375–82. https://doi.org/10.1111/cas.12088

Ma, Jun Li et al. “Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin.” Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine vol. 37,5 (2016): 6177–84. https://doi.org/10.1007/s13277-015-4458-z

Ma, Junli et al. “BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.” Cancer letters vol. 411 (2017): 117–129. https://doi.org/10.1016/j.canlet.2017.09.041

Kataoka, Junro et al. “Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.” Oncology reports vol. 35,5 (2016): 2576–82. https://doi.org/10.3892/or.2016.4681

Tiu, Yuen Chak et al. “GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.” Cancer gene therapy vol. 29,11 (2022): 1720–1730. https://doi.org/10.1038/s41417-022-00490-1

Manfredi, Giulia Francesca et al. “Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma.” Journal of hepatocellular carcinoma vol. 10 1955–1971. 3 Nov. 2023, https://doi.org/10.2147/JHC.S291553

Onuma, Amblessed E et al. “Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.” Gene expression vol. 20,1 (2020): 53–65. https://doi.org/10.3727/105221620X15880179864121

Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773–96. https://doi.org/10.1002/hep.32740.

Article  PubMed  Google Scholar 

Singal, Amit G et al. “Breakthroughs in Hepatocellular Carcinoma Therapies.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 21,8 (2023): 2135–2149. https://doi.org/10.1016/j.cgh.2023.01.039